A Seven-Year Follow-up of Men Following a Benign Prostate Biopsy
Objectives: To determine the incidence and clinical relevance of newly diagnosed cases of prostate cancer in a group of men who had an elevated PSA and benign prostate biopsy 7 years previously. Patients and Method: Patients under the age of 80 years with an elevated PSA who had had a benign prostat...
Gespeichert in:
Veröffentlicht in: | European urology 2003-07, Vol.44 (1), p.17-20 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Objectives:
To determine the incidence and clinical relevance of newly diagnosed cases of prostate cancer in a group of men who had an elevated PSA and benign prostate biopsy 7 years previously.
Patients and Method:
Patients under the age of 80 years with an elevated PSA who had had a benign prostate biopsy in the 12 months between March 1, 1994 and February 28, 1995 were studied.
One hundred and sixty four patients with a mean age of 66.8 years (range 47–79 years) were identified. The mean PSA for this group was 10.3
ng/ml (range 4.1–81
ng/ml). One hundred and fifty nine of the 164 (97%) hospital records were available for review and all but 21 (12.8%) of the General Practitioners were contacted.
Results:
Eighteen (11%) of the original 164 patients were subsequently diagnosed with prostate cancer, 2 died from their disease.
Conclusions:
In a population where the follow-up of patients with a benign biopsy was arranged on clinical grounds alone, 11% of the study group were diagnosed with prostate cancer during a seven-year follow-up. Although some of these cancers appear to be slow growing, most of those diagnosed in the initial follow-up period were deemed to be clinically significant and a small proportion progressed rapidly to metastases.
All patients who have an elevated PSA, but benign biopsy, should undergo a period of PSA monitoring until it is clear that their PSA is not rising. We propose an initial intensive monitoring period to avoid missing those with clinically aggressive disease. |
---|---|
ISSN: | 0302-2838 1873-7560 |
DOI: | 10.1016/S0302-2838(03)00205-7 |